The effects of medical therapy on insulin resistance and the cardiovascular system in PolyCystic Ovarian Syndrome

Completed

• Conditions: Polycystic ovarian syndrome; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN51367236
• Lead Sponsor: Southern Health (Australia)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-04-03
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 110

Inclusion Criteria

1. Overweight women (body mass index [BMI] greater than 27 kg/m^2)
2. Aged 18 - 40 years with PCOS diagnosed from a history of perimenarchal onset of irregular cycles (less than 21 days or greater than 35 days) plus clinical manifestations of hyperandrogenism (hirsutism, acne) or biochemical hyperandrogenism with elevation of at least one circulating ovarian androgen (1990 National Institute of Health [NIH] criteria)

Exclusion Criteria

1. BMI less than 27 kg/m^2
2. Other concurrent medical conditions
3. Ongoing use of the OCP
4. Pregnancy or desire for pregnancy
4. Secondary causes of amenorrhoea and hyperandrogenism

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effects on insulin resistance

Secondary Outcome Measures

Name	Time	Method
1. Clinical symptom improvement<br>2. Arterial function